Intravesicular cidofovir for BK hemorrhagic cystitis in pediatric patients after hematopoietic stem cell transplant

Pediatr Transplant. 2018 May;22(3):e13141. doi: 10.1111/petr.13141. Epub 2018 Feb 1.

Abstract

BK virus hemorrhagic cystitis is a complication of HCST. Response to IV cidofovir is unpredictable, and treatment carries risk of toxicity. We report the largest series of pediatric patients with BKHC after HSCT successfully treated with intravesicular cidofovir. There was no significant decrease in urine or plasma BK PCR. There was significant decrease in pain score on days 3 and 7, with associated decrease in morphine use. No patients experienced toxicities associated with IV cidofovir. Intravesicular cidofovir appears to be safe and effective for symptomatic treatment of BKHC in pediatric patients after HSCT.

Keywords: BK virus hemorrhagic cystitis; hematopoietic stem cell transplantation; intravesicular cidofovir.

Publication types

  • Case Reports

MeSH terms

  • Administration, Intravesical
  • Adolescent
  • Antiviral Agents / administration & dosage*
  • Antiviral Agents / therapeutic use
  • BK Virus*
  • Child
  • Cidofovir
  • Cystitis / drug therapy*
  • Cystitis / etiology
  • Cytosine / administration & dosage
  • Cytosine / analogs & derivatives*
  • Cytosine / therapeutic use
  • Female
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Male
  • Organophosphonates / administration & dosage*
  • Organophosphonates / therapeutic use
  • Polyomavirus Infections / drug therapy*
  • Polyomavirus Infections / etiology
  • Tumor Virus Infections / drug therapy*
  • Tumor Virus Infections / etiology

Substances

  • Antiviral Agents
  • Organophosphonates
  • Cytosine
  • Cidofovir